No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

© 2026 PharmaCountry. All rights reserved.

Privacy Policy Terms of Service Cookie Policy

Pen Tsao Chemical Industry Ltd sell "Raloxifen HCI (Under development)" | Pharmacountry

Products
Active Pharmaceutical Ingredients (APIs)
Other & Specialty APIs
Other Specialty/Unclassified APIs

Pen Tsao Chemical Industry Ltd sell "Raloxifen HCI (Under development)"

Pen Tsao Chemical Industry Ltd

Contract Manufacturer · Active Pharmaceutical Ingredients (APIs)

Ratings

(0)

(0)

(0)

(0)

(0)

Leave your rating & comment

Comments

Filters:

Sort by:

No comments available.

Matched Products & Services

B2B matches based on trade type, category, specifications & price range

Similar Products & Services

Products & Services related to what you're viewing

People Also Viewed

Other products & services viewed by people who looked at this product

Basic Information

187

8

4

4.4(36)

Category

Active Pharmaceutical Ingredients (APIs)

Subcategory & Sub-subcategory

Other & Specialty APIs / Other Specialty/Unclassified APIs

Trade Type

Sell

Product Name

Raloxifen HCI (Under development)

Details

Raloxifen HCI (Under development)

Substance

Raloxifene Hydrochloride

Specifications

CAS Number: 82640-04-8
EC Number: 639-789-7
Molecular Weight: 510
Chemical Formula: C₂₈H₂₈ClNO₄S
IUPAC Name: [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
Assay: Typically targeted at ≥98% purity by HPLC for generic API development batches
Impurity Profile: Related substances controlled per ICH Q3A limits during development
Polymorphic Form: Raloxifene HCl is known to exhibit polymorphism; crystalline form control is a key CMC consideration during development

Documents

Other

GMP